CA2558212C - Interferon-beta for anti-virus therapy for respiratory diseases - Google Patents

Interferon-beta for anti-virus therapy for respiratory diseases Download PDF

Info

Publication number
CA2558212C
CA2558212C CA2558212A CA2558212A CA2558212C CA 2558212 C CA2558212 C CA 2558212C CA 2558212 A CA2558212 A CA 2558212A CA 2558212 A CA2558212 A CA 2558212A CA 2558212 C CA2558212 C CA 2558212C
Authority
CA
Canada
Prior art keywords
ifn
cells
infection
agent
asthmatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2558212A
Other languages
English (en)
French (fr)
Other versions
CA2558212A1 (en
Inventor
Donna Elizabeth Davies
Peter Alexander Blanch Wark
Stephen Holgate
Sebastian L. Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to CA2787978A priority Critical patent/CA2787978A1/en
Publication of CA2558212A1 publication Critical patent/CA2558212A1/en
Application granted granted Critical
Publication of CA2558212C publication Critical patent/CA2558212C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2558212A 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases Expired - Lifetime CA2558212C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2787978A CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
GB0405634.7 2004-03-12
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2787978A Division CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (2)

Publication Number Publication Date
CA2558212A1 CA2558212A1 (en) 2005-09-22
CA2558212C true CA2558212C (en) 2012-11-27

Family

ID=32117582

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2787978A Abandoned CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
CA2558212A Expired - Lifetime CA2558212C (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2787978A Abandoned CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP1734987B1 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2787978A1 (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
JP5172679B2 (ja) * 2005-09-09 2013-03-27 インペリアル イノベーションズ リミテッド 呼吸器疾患の治療のためのインターフェロン−λ療法
WO2007035180A1 (en) * 2005-09-20 2007-03-29 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
EA201000785A1 (ru) * 2007-12-13 2011-02-28 Глаксо Груп Лимитед Композиции для доставки в легкие
WO2010123527A2 (en) * 2008-12-19 2010-10-28 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
WO2011067759A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
US9676819B2 (en) 2010-09-22 2017-06-13 Innavac Pty Ltd Immunostimulatory method
WO2015103749A1 (en) 2014-01-08 2015-07-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
WO2019023196A1 (en) * 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
WO2020168033A2 (en) * 2019-02-13 2020-08-20 University Of Florida Research Foundation, Inc. Targeting lung-resident tnfr2+ cdc2 (r2d2) subpopulation to treat asthma
EP3990428A4 (en) 2019-06-26 2023-07-19 ENA Respiratory Pty Ltd NOVEL MOLECULES
KR20230041097A (ko) 2020-07-20 2023-03-23 시네어젠 리서치 리미티드 SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
FI4240396T3 (fi) * 2020-11-04 2025-03-31 Ethris Gmbh IFN-lambda-mRNA virusinfektioiden hoitamiseksi
JP2024506803A (ja) * 2021-01-13 2024-02-15 アビオン インク． 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
EP1334128A2 (en) 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス，インコーポレイティド Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
EP1750749A2 (en) 2004-04-02 2007-02-14 ZymoGenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection

Also Published As

Publication number Publication date
US8273342B2 (en) 2012-09-25
EP2206512A2 (en) 2010-07-14
ATE466591T1 (de) 2010-05-15
DK1734987T3 (da) 2010-08-30
CA2787978A1 (en) 2005-09-22
US9089535B2 (en) 2015-07-28
EP1734987B1 (en) 2010-05-05
US20130209399A1 (en) 2013-08-15
JP2007528890A (ja) 2007-10-18
EP2206512A3 (en) 2013-01-09
GB0405634D0 (en) 2004-04-21
US20070134763A1 (en) 2007-06-14
US7569216B2 (en) 2009-08-04
WO2005087253A3 (en) 2005-11-24
CA2558212A1 (en) 2005-09-22
PT1734987E (pt) 2010-07-06
HK1097181A1 (en) 2007-06-22
WO2005087253A2 (en) 2005-09-22
EP1734987A2 (en) 2006-12-27
ES2343732T3 (es) 2010-08-09
DE602005021078D1 (de) 2010-06-17
JP2011144201A (ja) 2011-07-28
US20090257980A1 (en) 2009-10-15
PL1734987T3 (pl) 2010-10-29
JP4807526B2 (ja) 2011-11-02

Similar Documents

Publication Publication Date Title
CA2558212C (en) Interferon-beta for anti-virus therapy for respiratory diseases
Schloer et al. The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model
Clementi et al. Viral respiratory pathogens and lung injury
Gwyer Findlay et al. Cationic host defence peptides: potential as antiviral therapeutics
Park et al. Towards the application of human defensins as antivirals
Han et al. ZMPSTE24 regulates SARS-CoV-2 spike protein–enhanced expression of endothelial PAI-1
EP4130047A1 (en) Soluble ace2 and fusion protein, and applications thereof
Cipolla et al. Influenza sequelae: from immune modulation to persistent alveolitis
Peng et al. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
US20220008507A1 (en) Methods and compositions for treatment of coronavirus infection and associated coagulopathy
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
Abdul-Hafez et al. Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research
HK1146217A (en) Increase of interferon-beta for anti-virus therapy for respiratory diseases
HK1145985A (en) Increase of interferon-beta for anti-virus therapy for respiratory diseases
HK1097181B (en) Interferon-beta for anti-virus therapy for respiratory diseases
US20230355725A1 (en) Neil2 protein therapy for treatment of viral infection
Tavakol et al. The world against versatile SARS-Cov-2 nanomachines: mythological or reality?
CN114672474A (zh) 一种ace2突变体及其突变方法和应用
US7871603B2 (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
CA2632032C (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
EP4545091A1 (en) Transmembrane serine protease and neutrophil elastase inhibitors
WO2008134123A1 (en) Ul97 for treatment of protein aggregate disorders
Kolli et al. Alveolar Macrophages Contribute to the Pathogenesis of hMPV Infection While Protecting 1 Against RSV Infection 2

Legal Events

Date Code Title Description
EEER Examination request